Amphastar Pharmaceuticals Inc Aktie News

RANCHO CUCAMONGA, CA / ACCESS Newswire / October 27, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its third quarter of 2025 ended September 30, 2025, after the market closes on Thursday, November 6, 2025, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.

Amphastar Pharmaceuticals is rated a buy due to strong Q2 earnings, value metrics, and promising pipeline developments. AMPH beat revenue and EPS estimates in Q2, with BAQSIMI sales up 21% YoY, offsetting declines in legacy generics. The company is vastly expanding US manufacturing and advancing new drugs, including AMP-002 (recently FDA approved) and AMP-004 (insulin aspart generic).

RANCHO CUCAMONGA, CA / ACCESS Newswire / August 28, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Dan Dischner, SVP of Corp. Communication, will be participating in an Analyst-Moderated fireside chat at the 2025 Wells Fargo Healthcare Conference on Wednesday, September 3rd, 2025, at 12:45 pm ET. For access, visit Amphastar's Pharmaceuticals websi...

Agreement strengthens proprietary peptide pipeline targeting high-value oncology and ophthalmology indications RANCHO CUCAMONGA, CA / ACCESS Newswire / August 12, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar"), a biopharmaceutical company focused on developing, manufacturing, and marketing complex generic and proprietary injectable, inhalation, and intranasal products, today...

According to the FDA, Amphastar's iron sucrose injection meets the criteria for bioequivalence and therapeutic equivalence to Venofer ® for the treatment of iron deficiency anemia in patients with chronic kidney disease RANCHO CUCAMONGA, CA / ACCESS Newswire / August 11, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH), a biopharmaceutical company focused on developing, manufacturing, and m...

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH ) Q2 2025 Earnings Conference Call August 7, 2025 5:00 PM ET Company Participants Dan Dischner - Senior Vice President of Human Resources & Corporate Communication Tony Marrs - Executive VP of Regulatory Affairs & Clinical Operations William J. Peters - CFO, Executive VP of Finance, Treasurer & Director Conference Call Participants David A.

- Reports Net Revenues of $174.4 million for the Three Months Ended June 30, 2025 - GAAP net income of $31.0 million, or $0.64 per share, for the second quarter - Adjusted non-GAAP net income of $40.9 million, or $0.85 per share, for the second quarter - Company to hold a conference call today at 2:00 p.m. Pacific Time RANCHO CUCAMONGA, CA / ACCESS Newswire / August 7, 2025 / Amphastar Pharmace...

Amphastar is undervalued (~71% upside), but lacks an economic moat and faces modest growth, so I favor a cautious gradual strategy. The business is defensive, with a diversified product mix and pipeline, but faces headwinds from competition, tariffs, and patent expirations. My base-case DCF-based fair value is $38.23; even in a pessimistic scenario, the stock seems at least fairly valued, limit...